Key result
A relative decrease in 3D right ventricular longitudinal free wall strain of >12.4% after 4 cycles of chemotherapy predicted subsequent RV cardiotoxicity (AUC 0.80; P<0.001).
Why the study?
While early detection of left ventricular dysfunction is well studied during anthracycline therapy, little is known regarding early changes in right ventricular size and function.
Does 3-dimensional echocardiography predict anthracycline-induced right ventricular cardiotoxicity in patients with diffuse large B-cell lymphoma?
Cohort (n=74)
Does 3-dimensional echocardiography predict anthracycline-induced right ventricular cardiotoxicity in patients with diffuse large B-cell lymphoma?
Effect estimate: AUC 0.80
p-value: p=<0.001
Early changes in 3D echocardiography-derived right ventricular longitudinal free wall strain and end-systolic volume can predict subsequent anthracycline-induced right ventricular cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
May flag high-risk patients for closer monitoring during anthracycline therapy; hypothesis-generating and requires prospective validation before practice change.
Zhao et al. (2020) conducted a cohort in Diffuse large B-cell lymphoma receiving anthracycline-based treatment (n=74). 3DE-derived changes in right ventricular volumes and strains was evaluated on Right ventricular cardiotoxicity (relative reduction of >10% in 3D RVEF or >5% to a value of <45%) at the end of 6 cycles (AUC 0.80, p=<0.001). A relative decrease in 3D right ventricular longitudinal free wall strain of >12.4% after 4 cycles of chemotherapy predicted subsequent RV cardiotoxicity (AUC 0.80; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: